Fosun Pharma has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. for the cobmmercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US. Fosun Pharma will have the right to commercialise serplulimab upon approval in the US, and Henlius will retain responsibility for development, manufacturing, and supply.

For many years, the two companies have worked closely on product commercialisation and other areas, developing consensus in terms of corporate vision and values, global development strategy, product operations, and management communication while focusing on patients' and clinical needs. Through this collaboration, the two parties aim to intensively develop serplulimab, integrate superior resources, cooperate in securing approval, and promote its rapid launch in the United States to benefit more patients.